3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
4
Phase 2
2
Phase 4
1
Phase 3
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Thyroid Nodule
1
Prostatic Neoplasms
1
Endometrial Neoplasms
1
Coronary Artery Disease
1
Carcinoma, Renal Cell
1
Interventions
Zoledronic Acid
14
Leuprolide
9
bicalutamide
6
Triptorelin Pamoate
6
Goserelin
6
luprolide acetate gel depot
5
enzalutamide
5
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
5
Dutasteride
5
fluciclovine F-18
3
darolutamide
3
Sodium Chloride
3
Prednisone
3
Magnetic Resonance Spectroscopy
3
Flutamide
3
Androgen Antagonists
3
Abiraterone Acetate
3
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
3
cabazitaxel
2
Propofol
2
Prednisolone
2
Lidocaine
2
Gonadotropin-Releasing Hormone
2
Finasteride
2
Dexamethasone
2
Desflurane
2
Ciprofloxacin
2
testosterone 17 beta-cypionate
1
semaglutide
1
polyethylene glycol 3350
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Prostatic Neoplasms
×
High-Energy Shock Waves
×
Clear all
NCT01230905
2017-04-24
AST
Ottawa Heart Institute Research Corporation
Phase 4
Completed
181 enrolled